Literature DB >> 23498364

Surgical treatment results of intestinal and diffuse type gastric cancer. Implications for a differentiated therapeutic approach?

J Stiekema1, A Cats, A Kuijpers, F van Coevorden, H Boot, E P M Jansen, M Verheij, O Balague Ponz, M Hauptmann, J W van Sandick.   

Abstract

AIM: To study the outcome of patients who were surgically treated for primary gastric cancer with specific attention to differences in treatment results for intestinal and diffuse type tumours.
METHODS: All patients who underwent a potentially curative gastric resection between 1995 and 2011 in our institute were included. Patient, tumour and treatment characteristics were obtained retrospectively. Binary logistic and Cox regression models were used for multivariate analysis.
RESULTS: A consecutive series of 132 patients was included. Median follow-up was 53 months. There were no significant differences between patients with intestinal (N = 62) versus diffuse type (N = 70) gastric cancer with regard to the proportion of patients who underwent (neo)adjuvant treatment. Postoperative mortality was 2%. Pathological T- and N-stage were significantly more advanced for patients with diffuse type tumours. There was a significant difference in the percentage of microscopically irradical resections (2% versus 24%, p < 0.001) and median overall survival (129 versus 17 months, p < 0.001) between patients with intestinal type tumours and those with diffuse type tumours. On multivariate analysis, diffuse type histology was the only factor significantly associated with an R1 resection. In a multivariate Cox regression model, diffuse type histology was a significant adverse prognostic factor for overall survival.
CONCLUSIONS: Striking differences were found between patients with diffuse type tumours and those with intestinal type tumours. These differences call for a differentiated approach in the potentially curative treatment of these two tumour types.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23498364     DOI: 10.1016/j.ejso.2013.02.026

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  14 in total

Review 1.  Prevention and treatment of a positive proximal margin after gastrectomy for cardia cancer.

Authors:  Eider Talavera-Urquijo; Andrew R Davies; Bas P L Wijnhoven
Journal:  Updates Surg       Date:  2022-07-16

2.  Clinicopathological differences, risk factors and prognostic scores for western patients with intestinal and diffuse-type gastric cancer.

Authors:  Cristina Díaz Del Arco; Lourdes Estrada Muñoz; Luis Ortega Medina; Elena Molina Roldán; M Ángeles Cerón Nieto; Soledad García Gómez de Las Heras; M Jesús Fernández Aceñero
Journal:  World J Gastrointest Oncol       Date:  2022-06-15

3.  Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma.

Authors:  Miwako Kakiuchi; Takashi Nishizawa; Hiroki Ueda; Kengo Gotoh; Atsushi Tanaka; Akimasa Hayashi; Shogo Yamamoto; Kenji Tatsuno; Hiroto Katoh; Yoshiaki Watanabe; Takashi Ichimura; Tetsuo Ushiku; Shinichi Funahashi; Keisuke Tateishi; Ikuo Wada; Nobuyuki Shimizu; Sachiyo Nomura; Kazuhiko Koike; Yasuyuki Seto; Masashi Fukayama; Hiroyuki Aburatani; Shumpei Ishikawa
Journal:  Nat Genet       Date:  2014-05-11       Impact factor: 38.330

4.  Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis.

Authors:  Fausto Petrelli; Rosa Berenato; Luca Turati; Alessia Mennitto; Francesca Steccanella; Marta Caporale; Pierpaolo Dallera; Filippo de Braud; Ezio Pezzica; Maria Di Bartolomeo; Giovanni Sgroi; Vincenzo Mazzaferro; Filippo Pietrantonio; Sandro Barni
Journal:  J Gastrointest Oncol       Date:  2017-02

Review 5.  Resection line involvement after gastric cancer treatment: handle with care.

Authors:  Paolo Morgagni; Giuliano La Barba; Eleonora Colciago; Giovanni Vittimberga; Giorgio Ercolani
Journal:  Updates Surg       Date:  2018-06-23

6.  GEFT protein expression in digestive tract malignant tumors and its clinical significance.

Authors:  Yuanyuan Wang; Bing Zhang; Ge Gao; Yinping Zhang; Qingxin Xia
Journal:  Oncol Lett       Date:  2019-09-24       Impact factor: 2.967

7.  Genetic Gastric Cancer Risk Syndromes.

Authors:  Benjamin A Lerner; Xavier Llor
Journal:  Curr Treat Options Gastroenterol       Date:  2020-10-19

Review 8.  Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers.

Authors:  Rachel S van der Post; Ingrid P Vogelaar; Fátima Carneiro; Parry Guilford; David Huntsman; Nicoline Hoogerbrugge; Carlos Caldas; Karen E Chelcun Schreiber; Richard H Hardwick; Margreet G E M Ausems; Linda Bardram; Patrick R Benusiglio; Tanya M Bisseling; Vanessa Blair; Eveline Bleiker; Alex Boussioutas; Annemieke Cats; Daniel Coit; Lynn DeGregorio; Joana Figueiredo; James M Ford; Esther Heijkoop; Rosella Hermens; Bostjan Humar; Pardeep Kaurah; Gisella Keller; Jennifer Lai; Marjolijn J L Ligtenberg; Maria O'Donovan; Carla Oliveira; Hugo Pinheiro; Krish Ragunath; Esther Rasenberg; Susan Richardson; Franco Roviello; Hans Schackert; Raquel Seruca; Amy Taylor; Anouk Ter Huurne; Marc Tischkowitz; Sheena Tjon A Joe; Benjamin van Dijck; Nicole C T van Grieken; Richard van Hillegersberg; Johanna W van Sandick; Rianne Vehof; J Han van Krieken; Rebecca C Fitzgerald
Journal:  J Med Genet       Date:  2015-05-15       Impact factor: 6.318

9.  Trop2 is overexpressed in gastric cancer and predicts poor prognosis.

Authors:  Wei Zhao; Huijun Zhu; Shu Zhang; Hongmei Yong; Wei Wang; Yan Zhou; Bing Wang; Jinbo Wen; Zhenning Qiu; Guipeng Ding; Zhenqing Feng; Jin Zhu
Journal:  Oncotarget       Date:  2016-02-02

10.  Lauren classification and individualized chemotherapy in gastric cancer.

Authors:  Junli Ma; Hong Shen; Linda Kapesa; Shan Zeng
Journal:  Oncol Lett       Date:  2016-03-16       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.